On March 7, Sinqi Pharmaceutical issued an announcement on the “Double Improvement of Quality and Return” action plan. The company said that since its establishment, it has always attached importance to research and development of new products, and has made the development of new products with independent intellectual property rights the company's goal of continuous progress and innovation, and R&D investment has increased year by year. In the past three years (2020-2022), the company invested 84 million yuan, 118 million yuan, and 190 million yuan respectively, accounting for 12.13%, 11.47%, and 15.22% of revenue, respectively. After years of development, the company's R&D center has seven process technology platforms for conventional ophthalmic preparations, ophthalmic gels, and sustained-release formulations, as well as evaluation technology platforms for quality research, pharmacological drug substitution research, and drug packaging research. It also has functional departments covering all stages of ophthalmic drug development, such as the Clinical Medicine Department and the Registration Review Department.